Peptide research during the Cold War — the Soviet biology the West didn't see
10 min read · Uplevel editorial
In the mid-1970s, in a research institute on Kirochnaya Street in Leningrad, a scientist named Vladimir Khavinson was developing a hypothesis about aging that Western gerontologists would not encounter for another twenty years. The hypothesis was not, at its core, different from ideas circulating in American and European labs about cellular senescence and protein regulation. But the experimental program Khavinson built around it — isolating short peptide fractions from organ tissues and testing them for bioregulatory effects — proceeded in near-total isolation from Western pharmacology, published in Russian-language journals with limited international circulation, funded by the Soviet military through channels that made some of the research formally classified, and shaped by institutional traditions that valued multi-organ systems thinking over the single-target drug development that dominated Western pharmaceutical methodology.
The result was a body of research that is genuinely difficult to evaluate from outside: substantial in volume, consistent in certain findings, mechanistically plausible in places, and operating by standards of evidence that differ enough from FDA-aligned clinical trial methodology to make direct comparison treacherous.
The institutional context matters for understanding why this happened. Soviet pharmacology and physiology were organized differently from their Western counterparts. The Academy of Sciences ran large research institutes with substantial autonomy and multi-decade research programs that would have been difficult to sustain in Western academic funding cycles. The Institute of Experimental Medicine in Leningrad, where Khavinson built much of his career, was founded in 1890 and had a continuous institutional history that gave long-term research programs the kind of stability that grant-dependent Western labs could rarely achieve. The Institute of Molecular Genetics in Moscow operated in a similar tradition but with a different focus: neuroactive peptides and their potential for treating neurological and stress-related conditions.
The theoretical framework was also distinct. Western pharmacology in the 1960s and 1970s was increasingly dominated by the receptor-ligand model: identify a molecular target, synthesize a compound that binds it selectively, test the compound in animal models and then clinical trials. It was a powerful framework for small-molecule drug development. Soviet biomedical research, by contrast, maintained a stronger tradition of holistic organ-system thinking derived partly from Pavlovian physiology and partly from the broader Soviet emphasis on systems over reductionism. The concept of "bioregulators" — short peptides derived from tissues that could influence the functional state of those tissues and connected systems — fit naturally into this framework. Isolating an active fraction from thymus and testing it in thymus-adjacent immunological contexts was not considered inadequate; it was considered the natural starting point.
Khavinson's program produced a family of compounds now known as the Khavinson peptides or cytomaxes, each derived from specific organ sources. Thymalin came from thymus tissue. Cortexin from cerebral cortex. Retinalamin from retina. Epithalamin — and its synthetic descendant Epitalon — from the pineal gland. The purification process produced short peptide sequences, typically two to four amino acids, that Khavinson's group proposed were regulatory signals that tissues used to modulate their own gene expression. The proposed mechanism was epigenetic in the broad sense: these short peptides, administered exogenously, might enter cells and interact with histone proteins, influencing chromatin structure and thereby gene transcription in tissue-specific ways. This is a legitimate molecular mechanism; short peptides interacting with histones is not biologically implausible. The question is whether the specific peptides Khavinson's group isolated and tested act through this mechanism at the doses used, and whether the clinical effects reported in the Soviet and Russian literature are reproducible under controlled conditions.
Epitalon received the most attention outside Russia, largely because the anti-aging claims associated with it were specific and striking: extension of lifespan in animal models, possible effects on telomerase activity, normalization of circadian hormone patterns in aged animals and humans. The animal data, published across multiple papers in Russian and Eastern European journals between the 1990s and 2010s, showed consistent trends in rodent models. The human data — from Russian clinical studies in elderly populations — showed improvements in sleep architecture, immune parameters, and neuroendocrine function. These findings circulated in Western longevity and biohacking communities starting in the mid-2000s, largely through translation efforts by enthusiasts rather than academic channels, and Epitalon became one of the more commonly discussed Soviet-origin peptides in the compounding pharmacology space.
The Moscow program took a different approach. Semax and Selank, developed at the Institute of Molecular Genetics and related institutions, were designed as synthetic analogs of endogenous neuropeptides rather than tissue extracts. Semax is derived from ACTH(4-10), a fragment of adrenocorticotropic hormone; Selank is a synthetic analog of tuftsin, an immunomodulatory tetrapeptide. Both were developed explicitly as pharmacological compounds — they went through Soviet and Russian regulatory processes and are registered as approved drugs in Russia and some CIS countries. The research base for both is more methodologically consistent with Western standards than the tissue extract work: there are human studies with defined endpoints, published in peer-reviewed journals that also appear in PubMed, and the mechanism proposals involve receptors and signaling pathways that Western neuroscience recognizes.
The cardiac peptide research — Cortagen, derived from heart tissue — and the hepatoprotective peptide work represent other branches of the Khavinson family that have remained almost entirely within the Russian-language literature. These compounds are registered as medical products in Russia but have not been studied in FDA-aligned trials and are not available as compounded medications in the United States in the way that Semax and Selank are.
Why didn't this research cross? Several reasons operate simultaneously, and they're worth naming separately. Cold War scientific isolation was real but not absolute: there was scientific exchange, there were Soviet papers that made it into Western journals, and some Western scientists were aware of the work. The more persistent barriers were economic and methodological. The Soviet Union and later Russia had no obvious incentive to fund the kind of Western-standard clinical trials that would be required to file for FDA or EMA approval — the market for these compounds was domestic, the regulatory requirements were Russian, and the translation cost was enormous. The intellectual property landscape was also unfavorable: Soviet-era research was typically published without patents in the Western sense, and the economic infrastructure for licensing and commercializing the compounds in Western markets didn't exist during the period when the research was most active.
The methodological difference was also genuine and persists into how the literature is received. The Soviet and Russian research tradition produced many small studies with heterogeneous populations, variable controls, and outcomes measured by instruments that don't always map onto Western clinical trial endpoints. The studies are not fraudulent — they appear to be honest attempts to characterize real effects — but they don't meet the evidentiary standards that a Western regulatory submission requires, and independent replication outside Russia has been sparse. This is a legitimate scientific concern. It is also not the same as saying the biology doesn't exist.
The post-Soviet period brought partial bridge-building. Russian scientists publishing in English-language journals increased significantly after 1991. Some Khavinson-tradition papers appear in MDPI journals and other open-access venues that circulate in Western research communities. The longevity research community, through organizations like the International Longevity Alliance, has made some effort to integrate the Russian work into broader geroscience frameworks. Khavinson himself has been a participant in international aging conferences. The integration is real but incomplete, and the primary audience for most of this research outside Russia remains the wellness and biohacking community rather than academic pharmacology.
The current status is genuinely complicated. Semax and Selank are compounded medications available in the United States through licensed compounding pharmacies with a prescription; they are not FDA-approved drugs. The Khavinson cytomaxes are available through various channels but exist in a regulatory gray area that varies by jurisdiction. Epitalon circulates widely in research peptide markets. None of these compounds has completed the FDA approval process, and that fact carries real weight: it means the quality control, dosing standards, and safety data that come with approved drugs are absent.
The honest evaluation requires holding two things at once. The accumulated clinical experience in Russia with these compounds is substantial — decades of use in clinical populations with reported outcomes that are internally consistent. That experience is not nothing. It is also not a substitute for randomized controlled trials with blinded endpoints and pre-registered analysis plans. The biology underlying the tissue peptide concept is mechanistically plausible at a level of abstraction; whether the specific compounds act through the proposed mechanisms at clinically relevant doses is a different question. The Soviet-Russian peptide tradition represents a research program that deserves more rigorous Western replication than it has received — and until that replication happens, it cannot be evaluated by the standards that normally govern clinical decision-making.
What the Cold War peptide gap teaches about how science crosses political boundaries is not primarily about ideology. The ideological barriers to Soviet-Western scientific exchange were real, but they were not total. What persisted after the Cold War ended was an economic and institutional gap: a body of research that didn't fit the patent-driven, FDA-aligned development pathway that converts academic findings into approved drugs in Western markets. The research existed. It was published. It wasn't secret. But without the translation infrastructure — the capital, the clinical trial apparatus, the regulatory expertise — it remained visible only to those who looked for it in the original language.
Science crosses boundaries when there is a mechanism for it to do so. When that mechanism is absent — not because of secrecy but because of economics and institutional misalignment — the knowledge doesn't disappear. It waits for someone to build the bridge.
Frequently asked